In a significant advancement for Alzheimer’s disease treatment, the US Food and Drug Administration (FDA) granted approval to donanemab in early July. This groundbreaking therapy is designed for individuals with early-stage Alzheimer’s and represents the second treatment proven to slow the disease’s progression. Donanemab is also part of a trio of FDA-approved medications that effectively target and remove amyloid plaques from the brains of those affected by Alzheimer’s.
The recent wave of approvals, including donanemab, lecanemab, and aducanumab, has sparked optimism in the medical community as it marks a notable progression in addressing Alzheimer’s disease within just over three years. The impact of these therapies is hopeful as countries like Japan, South Korea, and China continue to explore new avenues in Alzheimer’s treatment.
